Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study - Takeaways - MDSpire

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study

  • By

  • Christopher G. Bunick

  • Ruth Ann Vleugels

  • Mark Lebwohl

  • April W. Armstrong

  • Ayman Grada

  • Emma Xiaomeng Yue

  • Madhi Saranadasa

  • Lani Wegrzyn

  • Elvira D’Andrea

  • February 22, 2026

  • 0 min

Share

  • 1

    Systemic corticosteroids are frequently prescribed for atopic dermatitis (AD), despite clinical guidelines recommending against their routine use.

  • 2

    One in five patients with AD received a systemic corticosteroid prescription, with nearly 25% of these prescriptions lasting over 90 days.

  • 3

    The study highlights a significant misalignment between real-world corticosteroid use and established clinical guidelines for AD treatment.

  • 4

    Advanced systemic therapies, including biologics and JAK inhibitors, offer safer alternatives to corticosteroids for managing moderate-to-severe AD.

  • 5

    There is a pressing need for broader adoption of corticosteroid-sparing treatments to improve care standards for patients with atopic dermatitis.

Original Source(s)

Assessment of Systemic Corticosteroid Use in Individuals with Atopic Dermatitis: Findings from a US Population Study

  • by Christopher G. Bunick, Ruth Ann Vleugels, Mark Lebwohl, April W. Armstrong, Ayman Grada, Emma Xiaomeng Yue, Madhi Saranadasa, Lani Wegrzyn, Elvira D’Andrea

  • February 22, 2026

Related Content

Medical Oddities: Muscle Memory Before Birth? 

When dad trains offspring gain, bar tricks can end in the OR, guts that linger, empathetic pain, and “natural” immune traps this week.

Amendment: Dupilumab Alleviates Itching in Various Dermatological Conditions: Insights from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.